JUPITER NEUROSCIENCES, INC. Employee Benefits and Share-based Compensation
JUPITER NEUROSCIENCES, INC. (JUNS) reported Employee Benefits and Share-based Compensation of $380.18 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for the quarter ending 2026-06-30 was $380.18K, a 0.00% change year-over-year.
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for the quarter ending 2026-03-31 was $381.23K, a 0.00% change year-over-year.
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for the quarter ending 2025-12-31 was $389.71K, a 56.40% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for the quarter ending 2025-09-30 was $389.71K.
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for fiscal 2025 was $1.55M, a 72.99% increase from fiscal 2024.
- JUPITER NEUROSCIENCES, INC. employee benefits and share-based compensation for fiscal 2024 was $893.78K.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 9 month as first filed | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $380.18K 10-Q · filed 2026-08-14 | $761.42K derived: sum of 2 quarters · filed 2026-08-14 | $1.15M derived: sum of 3 quarters · filed 2026-08-14 | $1.54M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $381.23K 10-Q · filed 2026-05-14 | $770.94K derived: sum of 2 quarters · filed 2026-05-14 | $1.16M derived: sum of 3 quarters · filed 2026-05-14 | $1.54M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $389.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $779.41K derived: sum of 2 quarters · filed 2026-04-01 | $1.16M derived: sum of 3 quarters · filed 2026-08-14 | $1.55M 10-K · filed 2026-04-01 | |
| 2025-09-30 | $389.71K 10-Q · filed 2025-11-14 | $769.89K derived: sum of 2 quarters · filed 2026-08-14 | $1.16M 10-Q · filed 2025-11-14 | $2.04M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $380.18K 10-Q · filed 2026-08-14 | $766.70K 10-Q · filed 2025-08-19 | $1.66M derived: sum of 3 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $381.23K 10-Q · filed 2026-05-14 | $1.28M derived: sum of 2 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $893.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $893.78K 10-K · filed 2026-04-01 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $504.08K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |